Otonomy

$2.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.43%) As of 4:00 PM EDT pre-market
-$0.01 (-0.43%) Pre-Market

Why Robinhood?

You can buy or sell Otonomy and other stocks, options, ETFs, and crypto commission-free!

About OTIC

Otonomy, Inc. Common Stock, also called Otonomy, is a biopharmaceutical company, which engages in the development of therapeutics for neurotology. Read More The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT); OTO-313 (gacyclidine) tinnitus; OTO-413 (BDNF) hidden hearing Loss; OTO-510 (otoprotectant) prevent CIHL; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan in April 2008 and is headquartered in San Diego, CA.

Employees
49
Headquarters
San Diego, California
Founded
2008
Market Cap
71.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
37.47K
High Today
$2.34
Low Today
$2.22
Open Price
$2.28
Volume
82.16K
52 Week High
$3.20
52 Week Low
$1.50

Collections

OTIC News

ReutersAug 3

Edited Transcript of OTIC earnings conference call or presentation 1-Aug-19 8:30pm GMT

7

OTIC Earnings

-$0.62
-$0.53
-$0.44
-$0.35
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, After Hours

More OTIC News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.